From creation, validation, and commercialization of innovative diagnostic assays to the discovery of new drug targets and novel medicine, our staff of experienced researchers utilize cutting-edge technologies to provide state-of-the-art services for our clients.
Oncoveda was established as a multi-discipline cancer research center in May of 2010 to facilitate a long-term cancer research and development program at Medical Diagnostic Laboratories LLC concentrating on early detection, monitoring, and treatment of gynecologic and urologic cancers.
Our goal is to understand tumor progression and response to chemotherapy, to identify cancer biomarkers and drug targets, and to translate our discoveries into clinical tests and small compound therapeutics that will contribute to the diagnosis and treatment of cancer.
Femeris Women’s Health Research Center is a multi-discipline research center within Medical Diagnostic Laboratories, L.L.C.(MDL) dedicated to discovery and development of diagnostic biomarkers, therapeutic targets, and engineered probiotics in the detection and treatment of obstetric and gynecologic infectious diseases and medical conditions.
Our goal is to understand medical issues that affect women’s health and translate our research findings to advance clinical analytics, drug discovery, and ultimately leading to medical therapy. We also serve as a resource for research collaborations and pre-clinical studies conducted by other members of GBG including MDL.
Institute of Metabolic DisordersWebsite
The Institute of Metabolic Disorders (IMD) focuses on drug discovery for the treatment of fatty liver disease (NAFLD/NASH). The Institute will strive to become a respected leader in the field of metabolic disease treatment. Our goal is to increase the quality of life for individuals with metabolic pathologies associated with loss of liver function.
Drug Discovery Services
Venenum Biodesign is a drug discovery company focused on advancing drug discovery programs at our novel targets to Pre-Clinical Drug Candidates, and seeking partners for clinical development. Our dual business model allows us to focus internally and develop public-private partnerships. The company was established with the mission of improving patients’ lives through the discovery of therapeutic compounds against our novel biological targets. Many of our targets involve novel protein-protein or protein-DNA interactions. Others are more conventional target classes (GPCRs, enzymes, NHRs etc.). Our goal is to advance our discoveries to medicine through partnership with pharmaceutical companies.
Venenum Biodesign utilizes state-of-the-art assay development and ultra-high throughput screening (UHTS) against our proprietary 5.5 million ECLiPS compound collection, protein engineering and production, cellular reagent generation, structural biology, medicinal chemistry, and in vivo models for our own platforms. We offer access to these capabilities, to academic institutions, non-profits, research organizations, and pharmaceutical companies.
Invivotek is a pre-clinical contract research organization specializing in translational studies. As a leading provider of preclinical in vivo testing, their award-winning vivarium facility featuring the most advanced laboratory technology and precise environmental controls, provides an ideal environment for custom and standard services to support the drug discovery and development programs of clients. Their testing of traditional and genetically modified rodent models of human disease is supported by biochemical and molecular biology techniques, as well as functional assays using primary cell cultures established from various mouse tissues under disease model and normal conditions. These assays provide tools to study the mechanism of action of various test therapeutics or potential target genes and to explore drug efficacy biomarkers.
Since 2003, PharmOptima has been advancing drug discovery and development in various therapeutic areas and has filled a niche in ocular drug development. PharmOptima’s in vivo services include studies in the fields of drug absorption, distribution, metabolism, and excretion (ADME), pharmacokinetics (PK), and pharmacology. They provides liquid chromatography and mass spectrometry (LC-MS/MS) bioanalysis in support of discovery and development programs, including method development and validation in accordance with regulatory guidelines. Their biochemistry expertise allows them to assess the role of biomarkers in numerous disease models. The biochemical capabilities include in vitro and cell based assay development for compound profiling as well as protein cloning and expression. Their expertise extends to the custom development of enzyme-linked immunosorbent assays (ELISA) and electrochemiluminescence multiplex formats.